Insys Therapeutics Company Profile (NASDAQ:INSY)

About Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INSY
  • CUSIP: N/A
  • Web: www.insysrx.com
Capitalization:
  • Market Cap: $640.45 million
  • Outstanding Shares: 72,696,000
Average Prices:
  • 50 Day Moving Avg: $9.45
  • 200 Day Moving Avg: $11.15
  • 52 Week Range: $8.70 - $15.06
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -73.42
  • P/E Growth: -1.09
Sales & Book Value:
  • Annual Revenue: $191.17 million
  • Price / Sales: 3.35
  • Book Value: $3.66 per share
  • Price / Book: 2.41
Profitability:
  • EBIDTA: ($8,730,000.00)
  • Net Margins: -9.63%
  • Return on Equity: -3.02%
  • Return on Assets: -2.34%
Debt:
  • Current Ratio: 3.13%
  • Quick Ratio: 2.81%
Misc:
  • Average Volume: 535,509 shs.
  • Beta: 0.87
  • Short Ratio: 20.18
 

Frequently Asked Questions for Insys Therapeutics (NASDAQ:INSY)

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Insys Therapeutics's stock split on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly minted shares were distributed to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics, Inc. (NASDAQ:INSY) released its earnings results on Thursday, August, 3rd. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.12. The firm had revenue of $42.60 million for the quarter, compared to analysts' expectations of $36.90 million. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. The firm's quarterly revenue was down 38.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.13 earnings per share. View Insys Therapeutics' Earnings History.

Where is Insys Therapeutics' stock going? Where will Insys Therapeutics' stock price be in 2017?

4 analysts have issued 1-year price objectives for Insys Therapeutics' shares. Their forecasts range from $10.00 to $14.00. On average, they expect Insys Therapeutics' share price to reach $12.67 in the next twelve months. View Analyst Ratings for Insys Therapeutics.

Who are some of Insys Therapeutics' key competitors?

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the folowing people:

  • Steven J. Meyer, Independent Chairman of the Board
  • Saeed Motahari, President, Chief Executive Officer, Director
  • Andrew G. Long, Chief Financial Officer
  • Franc Del Fosse, General Counsel, Corporate Secretary
  • John N. Kapoor Ph.D., Non-Independent Director
  • Rohit Vishnoi, Director
  • Patrick P. Fourteau, Independent Director
  • Pierre Lapalme, Independent Director
  • Brian Tambi, Independent Director

Who owns Insys Therapeutics stock?

Insys Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.24%), Dimensional Fund Advisors LP (0.79%), State Street Corp (0.65%), Northern Trust Corp (0.44%), FMR LLC (0.35%) and Regal Investment Advisors LLC (0.25%). Company insiders that own Insys Therapeutics stock include Daniel Brennan, John N Kapoor Trust Dated Sept, Patrick Fourteau, Rohit Vishnoi, Saeed Motahari, Steven J Meyer and Theodore H Stanley. View Institutional Ownership Trends for Insys Therapeutics.

Who sold Insys Therapeutics stock? Who is selling Insys Therapeutics stock?

Insys Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Gotham Asset Management LLC, Bowling Portfolio Management LLC, Tudor Investment Corp ET AL, Public Employees Retirement System of Ohio, GSA Capital Partners LLP, Regal Investment Advisors LLC, Vanguard Group Inc. and Virtu KCG Holdings LLC. View Insider Buying and Selling for Insys Therapeutics.

Who bought Insys Therapeutics stock? Who is buying Insys Therapeutics stock?

Insys Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Quantitative Investment Management LLC, Schneider Capital Management Corp, Strs Ohio, Marshall Wace North America L.P., State of Wisconsin Investment Board, State Street Corp and Voya Investment Management LLC. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept, Rohit Vishnoi, Saeed Motahari and Steven J Meyer. View Insider Buying and Selling for Insys Therapeutics.

How do I buy Insys Therapeutics stock?

Shares of Insys Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insys Therapeutics' stock price today?

One share of Insys Therapeutics stock can currently be purchased for approximately $8.81.


MarketBeat Community Rating for Insys Therapeutics (NASDAQ INSY)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  373
MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Insys Therapeutics (NASDAQ:INSY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $12.67 (43.78% upside)

Analysts' Ratings History for Insys Therapeutics (NASDAQ:INSY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/4/2017Royal Bank Of CanadaLower Price TargetOutperform -> Outperform$16.00 -> $14.00MediumView Rating Details
8/3/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldMediumView Rating Details
7/26/2017Piper Jaffray CompaniesSet Price TargetHold$10.00MediumView Rating Details
6/9/2017Jefferies Group LLCReiterated RatingBuy$14.00LowView Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageBuy$22.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$38.00 -> $30.00N/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Insys Therapeutics (NASDAQ:INSY)
Earnings by Quarter for Insys Therapeutics (NASDAQ:INSY)
Earnings History by Quarter for Insys Therapeutics (NASDAQ INSY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.09)$0.03$36.90 million$42.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.10)($0.09)$37.78 million$35.92 millionViewListenView Earnings Details
4/3/2017Q4 2016$0.00$0.03$52.08 million$54.86 millionViewN/AView Earnings Details
11/3/2016Q316$0.02$0.07$55.97 million$55.20 millionViewN/AView Earnings Details
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.16$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.40$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.48$52.77 million$55.70 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Insys Therapeutics (NASDAQ:INSY)
Current Year EPS Consensus Estimate: $-0.29 EPS
Next Year EPS Consensus Estimate: $-0.12 EPS

Dividends

Dividend History for Insys Therapeutics (NASDAQ:INSY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Insys Therapeutics (NASDAQ:INSY)
Insider Ownership Percentage: 67.90%
Institutional Ownership Percentage: 25.45%
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017John N Kapoor Trust Dated SeptMajor ShareholderBuy17,500$8.93$156,275.00View SEC Filing  
8/10/2017Saeed MotahariCEOBuy5,500$8.92$49,060.00View SEC Filing  
6/14/2017Saeed MotahariCEOBuy5,400$11.10$59,940.00View SEC Filing  
6/1/2017Rohit VishnoiDirectorBuy4,000$14.14$56,560.00View SEC Filing  
5/18/2017Steven J MeyerDirectorBuy8,000$12.21$97,680.00View SEC Filing  
5/16/2017Saeed MotahariCEOBuy4,500$11.98$53,910.00View SEC Filing  
11/4/2016Steven J MeyerDirectorBuy10,000$10.75$107,500.00View SEC Filing  
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.00View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.00View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.00View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.96View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.00View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.00View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.00View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.00View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.00View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.00View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.00View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.00View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.24View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.56View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.00View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.00View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.00View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.00View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.00View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Insys Therapeutics (NASDAQ:INSY)
Latest Headlines for Insys Therapeutics (NASDAQ:INSY)
Source:
DateHeadline
globenewswire.com logoINSYS Therapeutics Hires First Corporate Communications Leader and New Investor Relations Agency - GlobeNewswire (press release)
globenewswire.com - September 22 at 1:39 PM
finance.yahoo.com logoINSYS Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 22 at 1:39 PM
feeds.benzinga.com logoINSYS Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
feeds.benzinga.com - September 21 at 7:14 PM
finance.yahoo.com logoOur 5 Top Picks For A Booming Marijuana Market
finance.yahoo.com - September 20 at 9:33 PM
seekingalpha.com logoInsys Problems Keep Piling Up
seekingalpha.com - September 18 at 7:22 PM
reuters.com logoExclusive: Prosecutors identify Insys founder as unindicted co-conspirator in opioid case - Reuters
www.reuters.com - September 16 at 1:56 AM
seekingalpha.com logoTeva Looks to Hit Insys Where It Hurts - Seeking Alpha
seekingalpha.com - September 15 at 1:18 AM
finance.yahoo.com logoCompany under fire for opioid marketing files patent suit
finance.yahoo.com - September 15 at 1:18 AM
finance.yahoo.com logoETFs with exposure to INSYS Therapeutics, Inc. : September 14, 2017
finance.yahoo.com - September 15 at 1:18 AM
finance.yahoo.com logoINSYS Therapeutics, Inc. :INSY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 6:29 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Insys Therapeutics, Inc. (INSY) Will Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - September 13 at 8:08 PM
finance.yahoo.com logoHave Investors Already Priced In INSYS Therapeutics Inc’s (INSY) Growth?
finance.yahoo.com - September 13 at 2:52 AM
cnn.com logoReport: Drug company faked cancer patients to sell drug - CNN
www.cnn.com - September 8 at 1:17 AM
benzinga.com logoNemus Bioscience CEO Talks 'Waves Of Dominance' In The Cannabis Therapeutics Industry
www.benzinga.com - September 7 at 8:14 PM
reuters.com logoSenator reveals results of opioid inquiry into Insys
www.reuters.com - September 6 at 7:53 PM
finance.yahoo.com logo[$$] Opioid Maker Bent Rules to Get Drug to Patients, Senate Report Says
finance.yahoo.com - September 6 at 7:53 PM
finance.yahoo.com logoU.S. senator reveals results of opioid inquiry into Insys
finance.yahoo.com - September 6 at 7:53 PM
News IconArizona accuses Insys of fraudulent opioid marketing scheme
www.businessinsider.com - September 1 at 8:30 PM
reuters.com logoInsys rejects Arizona AG's claims drugmaker fueled opioid crisis
www.reuters.com - September 1 at 8:30 PM
finance.yahoo.com logoInsys Addresses Arizona Attorney General Complaint
finance.yahoo.com - September 1 at 8:30 PM
reuters.com logoPRESS DIGEST - Wall Street Journal - Sept 1 - Reuters
www.reuters.com - September 1 at 5:58 AM
reuters.com logoArizona accuses Insys of fraudulent opioid marketing scheme - Reuters
www.reuters.com - September 1 at 12:56 AM
reuters.com logoArizona accuses drugmaker Insys of fraudulent opioid marketing - Reuters
www.reuters.com - September 1 at 12:56 AM
msn.com logoAG filing lawsuit against Valley opioid company for alleged false claims, fraud
www.msn.com - August 31 at 7:54 PM
wsj.com logoArizona Accuses Insys of Fraudulently Marketing Fentanyl Painkiller
www.wsj.com - August 31 at 7:54 PM
finance.yahoo.com logo[$$] Arizona Accuses Insys of Fraudulently Marketing Fentanyl Painkiller
finance.yahoo.com - August 31 at 7:54 PM
finance.yahoo.com logoAG's office files lawsuit against opioid manufacturer Insys Therapeutics
finance.yahoo.com - August 31 at 7:54 PM
finance.yahoo.com logoArizona accuses drugmaker Insys of fraudulent opioid marketing
finance.yahoo.com - August 31 at 7:54 PM
americanbankingnews.com logoInsys Therapeutics, Inc. (INSY) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 29 at 2:34 AM
americanbankingnews.com logoInsys Therapeutics, Inc. (INSY) Expected to Announce Quarterly Sales of $35.29 Million
www.americanbankingnews.com - August 28 at 5:30 AM
americanbankingnews.com logoBidaskClub Upgrades Insys Therapeutics, Inc. (INSY) to "Sell"
www.americanbankingnews.com - August 26 at 4:22 PM
americanbankingnews.com logo Analysts Anticipate Insys Therapeutics, Inc. (INSY) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - August 26 at 10:48 AM
finance.yahoo.com logoCorporate News Blog - Insys Therapeutics Releases Statement on Illinois Settlement; Provides Data against the Opioid-Induced Calamity in the US
finance.yahoo.com - August 24 at 7:58 AM
streetinsider.com logoInsys Therapeutics (INSY) Issues Statement on Illinois Opioid Settlement - StreetInsider.com
www.streetinsider.com - August 23 at 5:23 AM
finance.yahoo.com logoInsys Addresses Questions Raised by Illinois Settlement
finance.yahoo.com - August 23 at 5:23 AM
reuters.com logoUPDATE 1-Insys agrees to pay $4.45 mln to resolve Illinois opioid lawsuit - Reuters
www.reuters.com - August 19 at 5:46 AM
reuters.com logoInsys agrees to pay $4.45 million to resolve Illinois opioid lawsuit - Reuters
www.reuters.com - August 19 at 5:46 AM
reuters.com logoInsys agrees to pay $4.45 million to resolve Illinois opioid lawsuit
www.reuters.com - August 18 at 7:42 PM
finance.yahoo.com logoInsys agrees to pay $4.45 mln to resolve Illinois opioid lawsuit
finance.yahoo.com - August 18 at 7:42 PM
seekingalpha.com logoInsys: Subsys Data Still Looks Anemic - Seeking Alpha
seekingalpha.com - August 17 at 12:55 AM
americanbankingnews.com logoInsys Therapeutics, Inc. (NASDAQ:INSY) Major Shareholder Purchases $156,275.00 in Stock
www.americanbankingnews.com - August 14 at 1:27 PM
americanbankingnews.com logoInsys Therapeutics, Inc. (INSY) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - August 13 at 10:14 AM
reuters.com logoJudge issues mixed ruling in Insys victim notification spat - Reuters
www.reuters.com - August 11 at 4:10 AM
americanbankingnews.com logoInsys Therapeutics, Inc. (INSY) CEO Purchases $49,060.00 in Stock
www.americanbankingnews.com - August 10 at 4:22 PM
americanbankingnews.com logoZacks: Analysts Anticipate Insys Therapeutics, Inc. (INSY) Will Announce Quarterly Sales of $35.25 Million
www.americanbankingnews.com - August 9 at 7:20 AM
nasdaq.com logoHenry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact - Nasdaq
www.nasdaq.com - August 8 at 7:34 PM
finance.yahoo.com logoOrthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2 - Yahoo Finance
finance.yahoo.com - August 8 at 7:33 PM
finance.yahoo.com logoInsulet (PODD) Shows Strength: Stock Adds 7.1% in Session
finance.yahoo.com - August 8 at 5:22 AM
americanbankingnews.com logoZacks: Analysts Expect Insys Therapeutics, Inc. (NASDAQ:INSY) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - August 8 at 12:30 AM
reuters.com logoAlabama 'pill mill' doctors tied to Insys lose bid to toss verdict - Reuters
www.reuters.com - August 8 at 12:20 AM

Social

Chart

Insys Therapeutics (INSY) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff